Overview of Psychiatric Disorders and the Role of Newer Antidepressants

Dennis S. Charney, MD; Dale R. Grothe, PharmD, BCPP; Sherry L. Smith, PharmD, BCPP; Kathleen T. Brady, MD, PhD; Juliana Kaltsounis-Puckett, PharmD, BCPP; Clinton W. Wright, PharmD, BCPP; Lyle K. Laird, PharmD, BCPP; A. John Rush, MD

J Clin Psychiatry 2002;63(suppl 1):3-3

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

4 The Course of Major Depressive Disorder. Dennis S. Charney, M.D.; Dale R. Grothe, Pharm.D., B.C.P.P.; and Sherry L. Smith, Pharm.D., B.C.P.P. From the Mood and Anxiety Disorders Research Program, National Institute of Mental Health, Bethesda, Md. (Dr. Charney); Medical Education Development Services, Comprehensive Neuroscience, Inc., Chevy Chase, Md. (Dr. Grothe); and the Neuroscience Medical Affairs Department, Bristol-Myers Squibb Company, Marietta, Ga. (Dr. Smith). Reprint requests to: Dennis S. Charney, M.D., Mood and Anxiety Disorders Research Program, National Institute of Mental Health, 9000 Rockville Pike, Bldg. 10, Room 4N222, Bethesda, MD 20892 (e-mail: [email protected]). 5 Major Depressive Disorder With Anxiety Symptoms or Sleep Disturbance. Kathleen T. Brady, M.D., Ph.D., and Juliana Kaltsounis-Puckett, Pharm.D., B.C.P.P. From the Department of Psychiatry, Medical University of South Carolina, Charleston (Dr. Brady); and the Neuroscience Medical Affairs Department, Bristol-Myers Squibb Company, Richmond, Va. (Dr. Kaltsounis-Puckett). Reprint requests to: Kathleen T. Brady, M.D., Ph.D., Department of Psychiatry, Medical University of South Carolina, 67 President St., P.O. Box 250861, Charleston, SC 29425 (e-mail: [email protected]). 7 Antidepressant Selection: Focus on Nefazodone. Clinton W. Wright, Pharm.D., B.C.P.P.; Lyle K. Laird, Pharm.D., B.C.P.P.; and A. John Rush, M.D. From the Neuroscience Medical Affairs Department, Bristol-Myers Squibb Company, San Antonio, Tex. (Dr. Wright); the Neuroscience Medical Affairs Department, Bristol-Myers Squibb Company, Denver, Colo. (Dr. Laird); the School of Pharmacy, University of Colorado Health Sciences Center, Denver (Dr. Laird); and the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (Dr. Rush). Reprint requests to: A. John Rush, M.D., Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9086 (e-mail: [email protected]